866-997-4948(US-Canada Toll Free)

Thyroid Cancer - Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Jun 2013

Category :

Cancer

No. of Pages : 280 Pages


Global Markets Direct’s, \'Thyroid Cancer - Pipeline Review, H1 2013\', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Thyroid Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Thyroid Cancer. Thyroid Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Thyroid Cancer.
  • A review of the Thyroid Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Thyroid Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Thyroid Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Thyroid Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
TABLE OF CONTENT

Introduction
Global Markets Direct Report Coverage
Thyroid Cancer Overview
Therapeutics Development
An Overview of Pipeline Products for Thyroid Cancer
Thyroid Cancer Therapeutics under Development by Companies
Thyroid Cancer Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Thyroid Cancer Therapeutics – Products under Development by Companies
Thyroid Cancer Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Thyroid Cancer Therapeutics Development
Bristol-Myers Squibb Company
F. Hoffmann-La Roche Ltd.
Biogen Idec Inc.
Sanofi-Aventis
AstraZeneca PLC
Daiichi Sankyo Company, Ltd
Merck & Co., Inc.
Emergent BioSolutions Inc.
Takeda Pharmaceutical Company Limited
Plexxikon Inc.
Reliance Life Sciences Pvt. Ltd.
Celltrion, Inc.
Bio-Path Holdings, Inc.
Novartis AG
Eisai Co., Ltd.
Genmab A/S
Sandoz Inc.
Exelixis, Inc.
Celgene Corporation
Bayer AG
EpiCept Corporation
IMMUNOMEDICS, INC
MethylGene Inc
Bionomics Limited
OXiGENE, Inc.
Accentia Biopharmaceuticals, Inc.
Pharmacyclics, Inc.
Cancer Research Technology Limited
Memgen, LLC.
Azaya Therapeutics, Inc.
Vascular Biogenics Ltd.
Globeimmune, Inc.
Biovista Inc.
AmpliMed Corporation
CureTech Ltd.
Genelux Corporation
Trophogen, Inc.
Thyroid Cancer – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
lenvatinib - Drug Profile
motesanib diphosphate - Drug Profile
pasireotide - Drug Profile
obinutuzumab - Drug Profile
sorafenib tosylate - Drug Profile
vandetanib - Drug Profile
vandetanib - Drug Profile
mocetinostat - Drug Profile
ibrutinib - Drug Profile
abexinostat hydrochloride - Drug Profile
SAR-245409 - Drug Profile
panobinostat - Drug Profile
dasiprotimut T - Drug Profile
docetaxel liposomal - Drug Profile
vemurafenib - Drug Profile
cabozantinib - Drug Profile
cabozantinib - Drug Profile
ISF-35 - Drug Profile
imexon - Drug Profile
VB-111 - Drug Profile
BMS-936564 - Drug Profile
pidilizumab - Drug Profile
BP-100-1.02 - Drug Profile
TRX-201 - Drug Profile
Autologous Recombinant Idiotypic Vaccine - Drug Profile
GI-6207 - Drug Profile
epratuzumab - Drug Profile
PLX-3397 - Drug Profile
buparlisib - Drug Profile
lithium carbonate - Drug Profile
lenalidomide - Drug Profile
DI-Leu16-IL2 Immunocytokine - Drug Profile
ofatumumab - Drug Profile
fosbretabulin disodium - Drug Profile
rituximab - Drug Profile
ocaratuzumab - Drug Profile
rituximab biosimilar - Drug Profile
rituximab biosimilar - Drug Profile
ETD-5 - Drug Profile
ABT-199 - Drug Profile
rituximab biosimilar - Drug Profile
Thyroid Stimulating Hormone Analog - Drug Profile
rituximab biosimilar - Drug Profile
PLX-4720 - Drug Profile
131I-Rituximab - Drug Profile
Drug Adaptation Program - Drug Profile
EDC-1 - Drug Profile
Andrographolide - Drug Profile
interferon alfa-2b biosimilar - Drug Profile
Drug For Lung and Thyroid Cancer - Drug Profile
GLONC-2 - Drug Profile
BVA-501 - Drug Profile
BVA-701 - Drug Profile
ONC-301 - Drug Profile
DNA Fusion Vaccines - Drug Profile
Thyroid Cancer Therapeutics – Drug Profile Updates
Thyroid Cancer Therapeutics – Discontinued Products
Thyroid Cancer Therapeutics - Dormant Products
Thyroid Cancer – Product Development Milestones
Featured News & Press Releases

Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Table


Number of Products Under Development for Thyroid Cancer, H1 2013
Products under Development for Thyroid Cancer – Comparative Analysis, H1 2013
Number of Products under Development by Companies, H1 2013
Number of Products under Development by Companies, H1 2013 (Contd..1)
Number of Products under Development by Companies, H1 2013 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H1 2013
Comparative Analysis by Late Stage Development, H1 2013
Comparative Analysis by Mid Clinical Stage Development, H1 2013
Comparative Analysis by Early Clinical Stage Development, H1 2013
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013
Products under Development by Companies, H1 2013
Products under Development by Companies, H1 2013 (Contd..1)
Products under Development by Companies, H1 2013 (Contd..2)
Products under Development by Companies, H1 2013 (Contd..3)
Products under Investigation by Universities/Institutes, H1 2013
Bristol-Myers Squibb Company, H1 2013
F. Hoffmann-La Roche Ltd., H1 2013
Biogen Idec Inc., H1 2013
Sanofi-Aventis, H1 2013
AstraZeneca PLC, H1 2013
Merck & Co., Inc., H1 2013
Takeda Pharmaceutical Company Limited, H1 2013
Plexxikon Inc., H1 2013
Reliance Life Sciences Pvt. Ltd., H1 2013
Celltrion, Inc., H1 2013
Bio-Path Holdings, Inc., H1 2013
Novartis AG, H1 2013
Eisai Co., Ltd., H1 2013
Genmab A/S, H1 2013
Sandoz Inc., H1 2013
Exelixis, Inc., H1 2013
Celgene Corporation, H1 2013
Bayer AG, H1 2013
IMMUNOMEDICS, INC, H1 2013
MethylGene Inc, H1 2013
Bionomics Limited, H1 2013
OXiGENE, Inc., H1 2013
Accentia Biopharmaceuticals, Inc., H1 2013
Pharmacyclics, Inc., H1 2013
Cancer Research Technology Limited, H1 2013
Memgen, LLC., H1 2013
Azaya Therapeutics, Inc., H1 2013
Vascular Biogenics Ltd., H1 2013
Globeimmune, Inc., H1 2013
Biovista Inc., H1 2013
AmpliMed Corporation, H1 2013
CureTech Ltd., H1 2013
Genelux Corporation, H1 2013
Trophogen, Inc., H1 2013
Assessment by Monotherapy Products, H1 2013
Assessment by Stage and Route of Administration, H1 2013
Assessment by Stage and Molecule Type, H1 2013
Thyroid Cancer Therapeutics – Drug Profile Updates
Thyroid Cancer Therapeutics – Discontinued Products
Thyroid Cancer Therapeutics – Dormant Products
Thyroid Cancer Therapeutics – Dormant Products (Contd..1)

List of Chart


Number of Products under Development for Thyroid Cancer, H1 2013
Products under Development for Thyroid Cancer – Comparative Analysis, H1 2013
Products under Development by Companies, H1 2013
Products under Investigation by Universities/Institutes, H1 2013
Late Stage Products, H1 2013
Mid Clinical Stage Products, H1 2013
Early Clinical Stage Products, H1 2013
Discovery and Pre-Clinical Stage Products, H1 2013
Assessment by Monotherapy Products, H1 2013
Assessment by Route of Administration, H1 2013
Assessment by Stage and Route of Administration, H1 2013
Assessment by Molecule Type, H1 2013
Assessment by Stage and Molecule Type, H1 2013

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *